Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Leerink Partners

Leerink Partners assumed coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a research note released on Tuesday morning, Marketbeat.com reports. The firm issued an outperform rating and a $31.00 target price on the technology company’s stock.

A number of other equities analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. TD Cowen started coverage on Aktis Oncology in a report on Tuesday. They issued a “buy” rating on the stock. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $31.67.

Aktis Oncology Stock Down 1.8%

Aktis Oncology stock opened at $19.57 on Tuesday. Aktis Oncology has a 12-month low of $18.02 and a 12-month high of $29.16.

Insider Buying and Selling

In related news, major shareholder Ansbert Gadicke acquired 1,112,777 shares of the stock in a transaction dated Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the purchase, the insider directly owned 10,260,064 shares in the company, valued at $184,681,152. This trade represents a 12.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm bought 1,112,777 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was bought at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the acquisition, the insider directly owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. This represents a 12.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 6,117,776 shares of company stock worth $110,119,968 over the last ninety days. Insiders own 3.30% of the company’s stock.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.